| abstract |
Phosphatidylinositol (PI) 3-kinase inhibitor compound, pharmaceutically acceptable salt thereof, and prodrug thereof; alone or in combination with at least one additional therapeutic agent, together with a pharmaceutically acceptable carrier A composition of said novel compound; and a novel compound, alone or in combination with at least one additional therapeutic agent, proliferative diseases, inflammatory and obstructive airway diseases, allergic conditions, autoimmunity and cardiovascular Use in the prevention or treatment of diseases characterized by abnormal activity of growth factors, protein serine / threonine kinases, and phospholipid kinases, including diseases. |